NEX Health Intelligence Raises $1.1M Pre‑seed Round Led by Brighteye Ventures

Why It Matters

Hospital‑acquired infections drive longer stays and higher costs; NEX’s AI solution could lower those expenses while improving patient safety, a priority for health systems worldwide.

Key Takeaways

• NEX raised €1M (~$1.09M) pre‑seed led by Brighteye Ventures.
• AI platform predicts and prevents hospital‑acquired infections.
• Platform already covered >40,000 patient admissions worldwide.
• Deployments at London NHS Trusts, Northwest England, and a Southeast Asian hospital.
• Funding will drive UK and global expansion and clinical evidence generation.

Pulse Analysis

Healthcare‑associated infections remain a costly, persistent threat, accounting for up to 15% of hospital admissions in high‑income nations. These infections extend patient stays, increase antimicrobial resistance, and inflate operational budgets. As payers and regulators tighten quality metrics, hospitals are seeking data‑driven tools that can intervene earlier than traditional surveillance methods. The market for infection‑prevention technology is therefore expanding rapidly, with investors eyeing solutions that combine real‑time analytics with actionable insights.

NEX Health Intelligence leverages machine‑learning models trained on electronic health records, microbiology data, and patient flow information to forecast transmission hotspots. By flagging at‑risk wards and patients, clinicians can deploy targeted hygiene protocols, isolate carriers, and adjust staffing before outbreaks materialize. Early adopters report higher compliance with infection‑control guidelines and a measurable drop in incident rates. The platform’s scalability—evidenced by deployments across two London NHS Trusts, a Northwest England trust, and a Southeast Asian military hospital—demonstrates its adaptability to diverse clinical environments and data ecosystems.

The €1 million seed injection, roughly $1.09 million, equips NEX to accelerate roll‑outs across the United Kingdom and penetrate additional international markets. Funds will also underwrite regulatory submissions and robust clinical‑economic studies needed to prove cost‑effectiveness to health‑system decision‑makers. As hospitals confront tightening budgets and heightened scrutiny over infection metrics, NEX’s evidence‑based AI could become a cornerstone of modern infection control, positioning the company for strategic partnerships and potential follow‑on financing.

Deal Summary

Healthtech startup NEX Health Intelligence announced it has closed a €1 million (~$1.1 million) pre‑seed funding round led by Brighteye Ventures, with participation from Adeline Arts & Science, AFI Ventures, Momentous Ventures and the Conception X Angel Syndicate. The capital will fund expansion of its AI‑driven infection intelligence platform across UK and international hospitals.